Abstract
The role of the immune system during and in response to acute myocardial infarction (MI) is poorly characterized but is an important driver of recurrent cardiovascular events. Anti-inflammatory drugs have shown promising effects on lowering this recurrency risk, but broadly impair the immune system and may induce severe side effects. To overcome these challenges a more detailed understanding of the immune response to myocardial infarction is needed.
For this, we compared peripheral blood mononuclear cell (PBMC) single-cell RNA-sequencing expression and plasma protein profiles over time (hospital admission, 24h and 6-8 weeks after STEMI) in 38 patients and in comparison to 38 controls (95,995 diseased and 33,878 control PBMCs). Compared to controls, we observed a relative increase in classical monocytes and a decrease in CD56dim natural killer cells in STEMI patients at admission, and these differences persisted until 24h after STEMI. The monocytes also showed the largest gene expression changes in each of the conditions, which was associated with changes in toll-like receptor, IFN and IL-1 signaling activity. Finally, a targeted protein cardiovascular biomarker panel revealed 33/92 plasma proteins to be changed after STEMI. Interestingly, three of these proteins were found to be affected by coronary artery disease-associated genetic risk variation, disease status and time after STEMI. Indicating the importance of taking all these aspects into consideration when defining potential future therapies.
Altogether, our analyses have revealed the immunological pathways that are disturbed upon MI, and in which cell type and during which stage of the disease this occurs. Additionally, we also provide insights in which patients are expected to benefit most from anti-inflammatory treatments, by identifying the genetic variants and disease stage at which these variants affect the outcome of these (drug-targeted) pathways. These findings advance our knowledge of the immune response after MI and provide further guidance for future therapeutic studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
LF is supported by the Dutch Organisation for Scientific Research (NWO) Corona Fast-Track grant (440.20.001), an Oncode Senior Investigator grant, NWO VIDI grant (917.14.374) and NWO VICI grant (09150182010019). MW is supported by a NWO VENI grant (192.029).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of LifeLines gave ethical approval for this work Ethics committee of CardioLines gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Updated figure 4
Data availability
Processed (de-anonymized) scRNA-seq data, including a text file that links each cell barcode to its respective individual, has been deposited at the European Genome-Phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAD00001010064.
Abbreviations
- AZU1
- Azurocidin
- CAD
- Coronary artery disease
- CHI3L1
- Chitinase-3-like-1
- CITE-seq
- Cellular indexing of transcriptomes and epitopes by sequencing
- CK
- Creatine kinase
- CK-MB
- Creatine kinase, myocardial band
- cMono
- Classical monocyte
- EDTA
- Ethylenediaminetetraacetic acid
- HbA1c
- Glycated hemoglobin
- C
- Control
- IGFBP1
- Insulin like growth factor binding protein
- 1 IL-1
- Interleukin 1
- IL6R
- Interleukin 6 receptor
- IL1RL1
- Interleukin 1 receptor-like 1
- LDL
- Low-density lipoprotein
- LFC
- Log fold change
- MAF
- Minor allele frequency
- MAST
- Model-based analysis of single cell transcriptomics
- MCV
- Mean corpuscular volume
- METC
- Medical ethical review committee
- MI
- Acute myocardial infarction
- MMP2
- Matrix metalloproteinase-2
- MPO
- Myeloperoxidase
- ncMono
- non-classical monocyte
- NT-proBNP
- N-terminal pro-brain natriuretic peptide
- PBMC
- Peripheral blood mononuclear cell
- PCI
- Percutaneous coronary intervention
- PCSK9
- Proprotein convertase subtilisin/kexin type 9
- pQTL
- Protein quantitative trait locus
- QC
- Quality check
- scATAC-seq
- Single-cell assay for transposase-accessible chromatin sequencing
- SNP
- Single-nucleotide polymorphism
- scRNA-seq
- Single-cell RNA-sequencing
- snRNA-seq
- Single-nucleus RNA-sequencing
- SPON1
- Spondin-1
- STEMI
- ST-elevated myocardial infarction
- TIMI
- Thrombosis in myocardial infarction
- UMAP
- Uniform manifold approximation and projection
- UMCG
- University medical center groningen
- UMI
- Unique molecular identifier
- VD
- Vessel disease
